BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US

Reuters01-23

BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US

** Shares of Cipla CIPL.NS edges up nearly 1% to 1,383 rupees ahead of Q3 results

** On avg, analysts expect about 20% y/y profit fall to 12.42 bln rupees ($135.6 mln), 5.7% rev rise to 74.76 bln rupees - data compiled by LSEG

** Jefferies expects strong Q3 for domestic pharma on robust growth in chronic therapies such as cardiac, diabetes, and respiratory

** Adds, generic-heavy businesses may be relatively muted

** Ambit Capital says co's India growth to improve on strong seasonal demand in core therapies

** Adds, co's U.S. market to be hit by falling generic multiple myeloma drug gRevlimid sales, partly offset by ramp-up in drugs for asthma, cancer treatment, hormone-related tumors

** Cipla rated 'hold' on avg by 36 analysts with median PT at 1,675 rupees; rival Sun Pharma SUN.NS rated 'buy' on avg, PT at 1,971.5 rupees - data compiled by LSEG

($1 = 91.6050 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

((Yagnoseni.Das@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605792421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 15:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605792421","market":"fut","top_or_hot":-1,"title":"BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US</title></head><body><p>** Shares of Cipla <span>CIPL.NS</span> edges up nearly 1% to 1,383 rupees ahead of Q3 results</p><p>** On avg, analysts expect about 20% y/y profit fall to 12.42 bln rupees ($135.6 mln), 5.7% rev rise to 74.76 bln rupees  - data compiled by LSEG</p><p>** Jefferies expects strong Q3 for domestic pharma on robust growth in chronic therapies such as cardiac, diabetes, and respiratory</p><p>** Adds, generic-heavy businesses may be relatively muted</p><p>** Ambit Capital says co's India growth to improve on strong seasonal demand in core therapies</p><p>** Adds, co's U.S. market to be hit by falling generic multiple myeloma drug gRevlimid sales, partly offset by ramp-up in drugs for asthma, cancer treatment, hormone-related tumors</p><p>** Cipla rated 'hold' on avg by 36 analysts with median PT at 1,675 rupees; rival Sun Pharma <span>SUN.NS</span> rated 'buy' on avg, PT at 1,971.5 rupees - data compiled by LSEG</p><p>($1 = 91.6050 Indian rupees)</p><p>(Reporting by Yagnoseni Das in Bengaluru)</p><p>((Yagnoseni.Das@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-23 15:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US</title></head><body><p>** Shares of Cipla <span>CIPL.NS</span> edges up nearly 1% to 1,383 rupees ahead of Q3 results</p><p>** On avg, analysts expect about 20% y/y profit fall to 12.42 bln rupees ($135.6 mln), 5.7% rev rise to 74.76 bln rupees  - data compiled by LSEG</p><p>** Jefferies expects strong Q3 for domestic pharma on robust growth in chronic therapies such as cardiac, diabetes, and respiratory</p><p>** Adds, generic-heavy businesses may be relatively muted</p><p>** Ambit Capital says co's India growth to improve on strong seasonal demand in core therapies</p><p>** Adds, co's U.S. market to be hit by falling generic multiple myeloma drug gRevlimid sales, partly offset by ramp-up in drugs for asthma, cancer treatment, hormone-related tumors</p><p>** Cipla rated 'hold' on avg by 36 analysts with median PT at 1,675 rupees; rival Sun Pharma <span>SUN.NS</span> rated 'buy' on avg, PT at 1,971.5 rupees - data compiled by LSEG</p><p>($1 = 91.6050 Indian rupees)</p><p>(Reporting by Yagnoseni Das in Bengaluru)</p><p>((Yagnoseni.Das@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nL4N3YN15B:1","article_id":"2605792421","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605792421","pubTimestamp":1769152365,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US** Shares of Cipla CIPL.NS edges up nearly 1% to 1,383 rupees ahead of Q3 results** On avg, analysts expect about 20% y/y profit fall to 12.42 bln rupees , 5.7% rev rise to 74.76 bln rupees  - data compiled by LSEG** Jefferies expects strong Q3 for domestic pharma on robust growth in chronic therapies such as cardiac, diabetes, and respiratory** Adds, generic-heavy businesses may be relatively muted** Ambit Capital says co's India growth to improve on strong seasonal demand in core therapies** Adds, co's U.S. market to be hit by falling generic multiple myeloma drug gRevlimid sales, partly offset by ramp-up in drugs for asthma, cancer treatment, hormone-related tumors** Cipla rated 'hold' on avg by 36 analysts with median PT at 1,675 rupees; rival Sun Pharma SUN.NS rated 'buy' on avg, PT at 1,971.5 rupees - data compiled by LSEG","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300485":"赛升药业","BK0012":"证金概念","BK0239":"医药制造","BK0046":"生物疫苗","BK0028":"国家队"},"translate_title":"嗡嗡声-预览-印度的西普拉攀升；分析师对国内盈利持乐观态度，对美国持谨慎态度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300485":0.9},"content_text":"BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US** Shares of Cipla CIPL.NS edges up nearly 1% to 1,383 rupees ahead of Q3 results** On avg, analysts expect about 20% y/y profit fall to 12.42 bln rupees ($135.6 mln), 5.7% rev rise to 74.76 bln rupees  - data compiled by LSEG** Jefferies expects strong Q3 for domestic pharma on robust growth in chronic therapies such as cardiac, diabetes, and respiratory** Adds, generic-heavy businesses may be relatively muted** Ambit Capital says co's India growth to improve on strong seasonal demand in core therapies** Adds, co's U.S. market to be hit by falling generic multiple myeloma drug gRevlimid sales, partly offset by ramp-up in drugs for asthma, cancer treatment, hormone-related tumors** Cipla rated 'hold' on avg by 36 analysts with median PT at 1,675 rupees; rival Sun Pharma SUN.NS rated 'buy' on avg, PT at 1,971.5 rupees - data compiled by LSEG($1 = 91.6050 Indian rupees)(Reporting by Yagnoseni Das in Bengaluru)((Yagnoseni.Das@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605792421","isCrawlerRequest":true}